Dublin-based APC is entering the Covid-19 vaccine space and will be hired for positions in chemistry, engineering, analytical science and supply chain.
Irish pharmaceutical research and development company APC is investing € 25 million in a new approach to vaccines that will create 120 jobs.
The company said the expansion at its Dublin headquarters will allow for rapid research and manufacturing of vaccines, including Covid-19 vaccines, as well as other advanced therapies for rare diseases.
An additional 12,000 square feet of laboratory space and research infrastructure are under construction at APC’s base in Cherrywood. This expansion, which involves an investment of 8 million euros, is expected to be fully operational by the end of June.
The company will add 50 new highly-skilled jobs to the existing team of 140, with roles in chemistry, biology, chemical engineering and analytical science starting immediately, along with other pharmaceutical positions.
This expansion will support research into Covid-19 vaccines and other advanced therapies.
‘This € 25 million investment is the culmination of our ambition for an Irish company to contribute to both the development and manufacturing of Covid vaccines.’
– BARRETT BRAND
Furthermore, APC is also investing € 17 in the creation of VLE Therapeutics, which will focus on the manufacture of vaccines and advanced therapies, including cell and gene therapies.
The company plans to have a new manufacturing facility by the end of 2021, with a large-scale annual capacity of up to 50 million doses of vaccine.
Up to 70 new jobs are planned as part of this investment, with roles in manufacturing operations, supply chain, engineering, and quality assurance and control.
Going forward, there are plans to have an 80,000-square-foot manufacturing facility by the end of 2023 that will manufacture a wide range of vaccines and advanced therapies, with a dose capacity of hundreds of millions.
APC was established in 2011 by CEO Dr. Mark Barrett and CTO Prof Brian Glennon, and has grown its pharmaceutical R&D business in South Dublin in recent years.
In 2020, the company announced plans to help develop a candidate vaccine for Covid-19. He also created VLE Therapeutics to focus on manufacturing.
In addition to researching and manufacturing the Covid-19 vaccine, APC is also working on drugs for a variety of cancers, respiratory diseases, Alzheimer’s disease, and HIV.
“In development since July 2020, this € 25 million investment is the culmination of our ambition for an Irish company to stand firm and contribute, both domestically and globally, to the development and manufacture of Covid vaccines and other advanced therapies. critics”. Barrett said.
“Ireland is a global pharmaceutical manufacturing powerhouse and we believe that our technological advancements can work hand in hand with this track record to accelerate the development and manufacture of these critical vaccines and advanced therapies for people in Ireland, Europe and across the world. the world. “
Enterprise Ireland is supporting investment in APC’s new research facilities and VLE Therapeutics new business. The agency’s chief executive, Leo Clancy, said APC has a history of “delivering disruptive, game-changing technology” to global pharmaceutical companies.
“Today’s announcement is enormously significant in reaching the next frontier in biopharmaceutical manufacturing and further strengthens Ireland’s position in the global vaccine development and manufacturing value chain,” he added.
Taoiseach Michael Martin, TD, said the new facility “would revolutionize the way drugs are developed and delivered to patients.”
“The fact that all of this is happening in Ireland is testament to the wealth of talent and vision that we have here in this country in the biotech and pharmaceutical space. It is remarkable to think that, thanks to APC and VLE, Ireland will soon have the capacity to manufacture hundreds of millions of doses of vaccines per year. “
You can find more information about jobs at APC on your website.